Takeda UK boss retains role after Shire acquisition

22 January 2019

The man leading the UK and Ireland operations in what Takeda (TYO: 4502) calls the company’s ‘new phase’ will be Jon Neal, it has been confirmed.

Japanese drugmaker Takeda has just completed the $62 billion acquisition of Ireland-headquartered rare disease specialist Shire, in the process becoming one of the world’s top 10 pharma companies by revenue.

With the political uncertainty and size of Takeda and formerly Shire’s presence in the two countries, the UK and Ireland is an important focus for the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK